financetom
Business
financetom
/
Business
/
Lucky Strike maker BAT sees stronger H2 revenue growth in new category, combustibles
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lucky Strike maker BAT sees stronger H2 revenue growth in new category, combustibles
Dec 10, 2024 11:33 PM

(Reuters) -British American Tobacco ( BTI ) on Wednesday forecast stronger revenue growth in its new category, which includes vapes and oral nicotine products, and combustibles in the second half of the year, driven by increased investments in the United States.

The maker of Lucky Strike and Dunhill cigarettes said it remains on track to meet its 2024 outlook of low-single-digit organic revenue and adjusted profit growth.

"In the United States, I am encouraged that our investment approach, taken over the last 18 months to strengthen our business, is working despite a challenging macro-economic backdrop," CEO Tadeu Marroco said in a statement.

BAT, along with Philip Morris and Japan Tobacco, is set to pay C$32.5 billion ($22.94 billion) to settle a long-running tobacco lawsuit in Canada, as part of a proposed plan by a court-appointed mediator, Philip Morris said in October.

The British firm said on Tuesday it expects clearer details on the financial impact of the settlement when it releases its 2025 forecast in February.

($1 = 1.4169 Canadian dollars)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Altimmune Reports 'Significant' Drop in Inflammatory Lipids With Pemvidutide in Liver Disease Treatment
Altimmune Reports 'Significant' Drop in Inflammatory Lipids With Pemvidutide in Liver Disease Treatment
Nov 15, 2024
12:15 PM EST, 11/15/2024 (MT Newswires) -- Altimmune ( ALT ) said Friday that data from its phase 1b testing of its pemvidutide drug candidate showed reductions in various inflammatory lipid species linked to cardiovascular risks in individuals with metabolic dysfunction-associated steatotic liver disease. Pemvidutide, a balanced GLP-1/glucagon dual receptor agonist, is under development for treating metabolic dysfunction-associated steatohepatitis and...
Vir Biotechnology Reports Promising Results for Potential Chronic Hepatitis B Combination Treatments
Vir Biotechnology Reports Promising Results for Potential Chronic Hepatitis B Combination Treatments
Nov 15, 2024
12:06 PM EST, 11/15/2024 (MT Newswires) -- Vir Biotechnology ( VIR ) said Friday results from part B of a phase 2 trial assessing combinations of tobevibart and elebsiran to treat chronic hepatitis B showed promising rates of hepatitis B surface antigen loss in participants with low baseline levels, particularly when combined with pegylated interferon alfa. The study included 51...
Market Chatter: McDonald's Plans $35 Million in Marketing After E. Coli Outbreak
Market Chatter: McDonald's Plans $35 Million in Marketing After E. Coli Outbreak
Nov 15, 2024
12:12 PM EST, 11/15/2024 (MT Newswires) -- McDonald's (MCD) earmarked $35 million for marketing to help the US business recover from the impact of last month's E. coli outbreak, which was tied to the company's Quarter Pounders, The Wall Street Journal reported Friday, citing an internal message. The planned investments include new advertisements focused on the company's food, the report...
--McDonald's Onion Supplier Faces Class Action Lawsuit Over E. Coli Outbreak
--McDonald's Onion Supplier Faces Class Action Lawsuit Over E. Coli Outbreak
Nov 15, 2024
12:08 PM EST, 11/15/2024 (MT Newswires) -- Price: 291.59, Change: -6.98, Percent Change: -2.34 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved